HOME >> BIOLOGY >> NEWS
Hemocellular Therapeutics establishes licensing agreement with UNC, ECU

CHAPEL HILL -- Hemocellular Therapeutics, expected to produce the first platelet-based therapeutic available to doctors for the immediate treatment of active bleeding, has established an exclusive licensing agreement with the University of North Carolina at Chapel Hill and East Carolina University, company officials recently announced.

The agreement recognizes key technology developed by researchers at the two universities as central to the N.C. company's planned creation of lyophilized, or "freeze-dried," human platelets the component of blood primarily responsible for initiation of coagulation. As a part of the exclusive license agreement, both universities received equity in Hemocellular and will share in royalties on the eventual sale of products.

Hemocellular's freeze-dried platelets are the result of a decade of research supported by initial federal research funding of $10 million.

The company's scientific founders, Dr. Arthur P. Bode of ECU and Dr. Thomas H. Fischer of UNC, have led the research efforts. Bode, who received his doctorate in experimental pathology from UNC, has served as ECU's scientific director of clinical coagulation programs for 15 years.

Fischer is scientific director of UNC's Francis Owen Research Laboratory, where researchers discovered the molecular cell membrane cross-linking technology crucial to Hemocellular's product development, said Richard A. Basile, chief executive officer of the company, and the initial extensive series of trials have taken place at that lab.

"The Francis Owen lab has a worldwide reputation in the field of coagulation therapeutics. We are extremely fortunate to have researchers affiliated with this lab informing our efforts to bring this technology to health-care settings as rapidly and responsibly as possible," he said.

Basile added that the licensing agreement is key in advancing platelet development to the next stage: human clinical trials. No other func
'"/>

Contact: Deb Saine
919-962-8415
University of North Carolina at Chapel Hill
15-May-2003


Page: 1 2 3

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
4. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
5. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
6. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
7. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
8. Immerge BioTherapeutics announces identification of PERV receptor
9. Acorda Therapeutics acquires CeNeS neuregulin products
10. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
11. Genome Therapeutics, University of Southampton and Schering-Plough identify novel asthma gene

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2019)... ... August 14, 2019 , ... Gateway Genomics , a leading ... inclusion in the 38th annual Inc. 500|5000 list of fastest growing private ... companies must have been founded and generating revenue by March 31, 2015. Ranking in ...
(Date:8/14/2019)... ... ... Julie Reck of Veterinary Medical Center of Fort Mill has recently begun providing ... her own geriatric Australian Shepherd, Simon, was treated in June 2019 for osteoarthritis in his ... body was weak, and he struggled to play fetch and other games with his family. ...
(Date:8/6/2019)... ... August 06, 2019 , ... A study released today in ... far-reaching implications for personalized medicine, especially when seeking treatments for children with heart ... which stem cell donors and manipulation methods might yield the best therapies for ...
Breaking Biology News(10 mins):
(Date:9/11/2019)... (PRWEB) , ... September 09, 2019 , ... ... life sciences companies and government agencies, announced that its president and CEO Maryann ... of successful business leaders. , The Forbes Council accepted Gallivan based on the ...
(Date:9/8/2019)... YORK (PRWEB) , ... September 04, 2019 , ... ... New York Academy of Sciences announced today the three Winners and six ... outstanding postdoctoral scientists from academic research institutions across New York, New Jersey, and ...
(Date:8/29/2019)... ... August 28, 2019 , ... DuPont Nutrition & Biosciences will ... at the International Baking Industry Expo, September 8 to 11, in booth 5015. ... to cost and waste reduction and from maintaining freshness throughout shelf life to ...
(Date:8/23/2019)... ... ... The EnozoPro® converts ordinary tap water into a sanitizing spray capable of ... including E. Coli, Salmonella, MRSA, Listeria and Legionella. It works as a cleaner, sanitizer ... page at rovingblue.com , ”At Enozo, our mission is to develop solutions to replace ...
Breaking Biology Technology:
Cached News: